ROARABLE // PRO
GLOBAL DESKS // NYC --:--:-- NYSE
US TAPE
ROAR ▸
COMP <GO>

IRWD vs CLYM // EV/EBITDA & P/E VALUATION

Ironwood Pharmaceuticals Inc. (Class A) (NASDAQ) VS. Climb Bio Inc. (NASDAQ) • 15-METRIC TALLY: IRWD 4 — CLYM 1
■ METRIC PARITY
15-METRIC INSTITUTIONAL SIDE-BY-SIDE SCORECARD (IRWD VS. CLYM) EMERALD CELL = QUANTITATIVE EDGE
INSTITUTIONAL METRIC IRWD CLYM SPREAD (A - B) ADVANTAGE DEDICATED URL
Gross Profit Margin — — — TIE /gross-margins <GO>
Return on Invested Capital (ROIC) 85.00% -35.00% +120.00 IRWD /roic <GO>
EV/EBITDA & P/E Valuation ACTIVE 3.9x — — TIE /valuation <GO>
Free Cash Flow Yield 21.23% -9.19% +30.42 IRWD /fcf-yield <GO>
Operating Margin 33.30% — — TIE /operating-margins <GO>
Net Profit Margin 8.10% — — TIE /net-margins <GO>
Revenue Growth (YoY) -15.70% — — TIE /revenue-growth <GO>
Dividend Yield & FCF Payout Safety 0.00% 0.00% 0.00 TIE /dividend-safety <GO>
Altman Z-Score & Debt/Equity 0.20 — — TIE /balance-sheet <GO>
Piotroski F-Score Quality 7/9 3/9 +4.00 IRWD /piotroski-score <GO>
Options Implied Move & Put/Call Skew — — — TIE /options-implied-move <GO>
RSI-14 & 200D SMA Momentum 40.5 44.1 -3.60 CLYM /rsi-technicals <GO>
10Y Yield & FRED Macro Beta — — — TIE /macro-sensitivity <GO>
Forward P/E Multiple 23.2x — — TIE /forward-pe <GO>
Enterprise Scale & Market Cap $598.2M $593.3M $4.9M IRWD /market-cap <GO>
5-YEAR HISTORICAL XBRL REVENUE & MARGIN TRAJECTORY SEC FORM 10-K FY
FISCAL YEAR IRWD REV CLYM REV IRWD GROSS % CLYM GROSS % IRWD FCF CLYM FCF
FY 2025 $296.2M $0 — — $127.0M -$54.5M
FY 2024 $351.4M $0 — — $103.4M -$15.6M
FY 2023 $442.7M $0 — — $183.4M -$20.6M
FRED MACRO REGIME CORRELATION COMPARISON PEARSON r
IRWD // BETA —
CLYM // BETA —